Пути улучшения эффективности эндокринотерапии рака молочной железы: новые таргетные мишени, новые терапевтические возможности


В.Ф. Семиглазов (1), В.В. Семиглазов (2), К.С. Николаев (1), Г.А. Дашян (1), А.В. Комяхов (1) , Р.М. Палтуев (1), В.С. Апполонова (1), Р.В. Донских (1), А.И. Целуйко (1), Т.Ю. Семиглазова (1), Е.К. Жильцова (1), П.В. Криворотько (1)

1 НИИ онкологии им. Н.Н. Петрова, Санкт-Петербург, Россия; 2 Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова, Санкт-Петербург, Россия
Преодоление резистентности к эндокринотерапии является одним из наиболее сложных аспектов лечения рака молочной железы (РМЖ). Исследования резистентности к гормональной терапии показали фундаментальную роль перекрестных сигнальных путей во взаимодействии с рецепторами эстрогенов, определяющих резистентность (пути PI3K/AKT/mTOR). Ингибитор mTOR эверолимус улучшает выживаемость больных гормон-рецептор-положительным РМЖ. Активация пути CDK4/CDK6/E2T является частым признаком люминального ER+РМЖ. Комбинация ингибитора CDK4/6 рибоциклиба с летрозолом продемонстрировала достоверное увеличение беспрогрессивной выживаемости в сравнении с летрозолом+плацебо. Комбинация ингибитора CDK 4/6 палбоциклиба и фулвестранта показала значительное улучшение беспрогрессивной выживаемости по сравнению с фулвестрантом+плацебо.

Литература


1. Семиглазов В.Ф., Семиглазов В.В. Лечение рака молочной железы. Клинико-биологическое обоснование. М., 2017. 272 с.

2. Beatson G.T. On the treatment of inoperable carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet. 1896;2:104–7.

3. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Davies C., Godwin J., Gray R., Clarke M.,et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:771–84.

4. Mauri D., Pavlidis N., Polyzos N.P., Ioannidis J.P.Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J. Natl. Cancer Inst. 2006;98:1285–91.

5. Osborne C.K., Schiff R. Estrogen-receptor biology: continuing progress and therapeutic implications. J. Clin. Oncol. 2005;23:1616–22.

6. Egeland N.G., Lunde S., Jonsdottir K., et al.The role of MicroRNAs as predictors of response to tamoxifen treatment in breast cancer patients. Int. J. Mol. Sci. 2015;16:24243–75.

7. Campbell R.A., Bhat-Nakshatri P., Patel N.M., et al. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J. Biol. Chem. 2001;276:9817–24.

8. Robinson D.R., Wu Y.M., Vats P., et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat. Genet. 2013;45:1446–51.

9. Nardone A., De Angelis C., Trivedi M.V., et al. The changing role of ER in endocrine resistance. Breast. 2015;24(suppl 2):S60–6.

10. Zhang Q-X., Borg A., Wolf D.M., et al. An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer Res. 1997;57:1244–49.

11. Merenbakh-Lamin K., Ben-Baruch N., Yeheskel A.,et al. D538G mutation in estrogen receptor-a: A novel mechanism for acquired endocrine resistance in breast cancer. Cancer Res. 2013;73:6856–64.

12. Diehl F., Li M., Dressman D., et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc. Natl. Acad. Sci. USA. 2005;102:16368–73.

13. Takeshita T., Yamamoto Y., Yamamoto-Ibusuki M., Iet al. Droplet digital polymerase chain reaction assay for screening of ESR1 mutations in 325 breast cancer specimens. Transl. Res. 2015;166:540–53.e2.

14. Fribbens C., O’Leary B., Kilburn L., et al. Plasma ESR1 mutations and the treatment of estrogen receptor–positive advanced breast cancer. J. Clin. Oncol. 2016;34:2961–68.

15. Finn R.S., Dering J., Conklin D., et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11:R77.

16. Saxena R., Dwivedi A. ErbB family receptor inhibitors as therapeutic agents in breast cancer: Current status and future clinical perspective. Med. Res. Rev. 2012;32:166–215.

17. Dowsett M. Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. Endocr. Relat. Cancer. 2001;8:191–95.

18. Ejlertsen B., Aldridge J., Nielsen K.V., et al.; Danish Breast Cancer Cooperative Group; BIG 1–98 Collaborative Group; International Breast Cancer Study Group. Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial. Ann Oncol. 2011;23:1138–44.

19. Perez E.A., Romond E.H., Suman V.J., et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J. Clin. Oncol. 2011;29:3366–73.

20. Schwartzberg L.S., Franco S.X., Florance A., et al. Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer. Oncologist. 2010;15:122–29.

21. Bose R., Kavuri S.M., Searleman A.C., et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov. 2013;3:224–37.

22. Hyman D.M., Piha-Paul S.A., Rodón J., et al.Neratinib for ERBB2 mutant, HER2 non-amplified, metastatic breast cancer: preliminary analysis from a multicenter, open-label, multi-histology phase II basket trial. Cancer Res. 2016;76 (suppl 4):abstr PD5–05.

23. Wolff A.C., Lazar A.A., Bondarenko I., et al. Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J. Clin. Oncol. 2013;31:195–202.

24. Baselga J., Semiglazov V., van Dam P., et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J. Clin.Oncol. 2009;27:2630–37.

25. Bachelot T., Bourgier C., Cropet C., et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J. Clin. Oncol. 2012;30:2718–24.

26. Yardley D.A., Noguchi S., Pritchard K.I., et al.Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv. Ther. 2013;30:870–84.

27. Piccart M., Hortobagyi G.N., Campone M., et al.Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. Ann. Oncol. 2014;25:2357–62.

28. Campone M., Bachelot T., Gnant M., et al. Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study. Eur. J. Cancer. 2013;49:2621–32.

29. Baselga J., Campone M., Piccart M., et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 2012;366:520–29.

30. Rugo H.S., Pritchard K.I., Gnant M., et al. Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. Ann. Oncol. 2014;25:808–15.

31. Dean J.L., Thangavel C., McClendon A.K., et al.|Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure. Oncogene. 2010;29:4018–32.

32. Krop I., Johnston S., Mayer I., et al. The FERGI phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus placebo in patients with ER+, aromatase inhibitor (AI)-resistant advanced or metastatic breast cancer – Part I results. Cancer Res. 2015;75:S2–02.

33. Baselga J., Im S.A., Iwata H., et al. PIK3CA status in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR+/HER2– advanced breast cancer (BC): First results from the randomized, phase III BELLE-2 trial. Cancer Res. 2015;76(4 suppl):abstr S6–01.

34. Finn R.S., Crown J.P., Lang I., et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16:25–35.

35. Turner N., Grose R. Fibroblast growth factor signalling: from development to cancer. Nat. Rev. Cancer. 2010;10:116–19.

36. Juric D., Ismail-Khan R., Campone M., et al.Phase Ib/II study of ribociclib and alpelisib and letrozole in ER+, HER2– breast cancer: Safety, preliminary efficacy and molecular analysis. Cancer Res. 2016;76(suppl 4):abstr P3-14–01.

37. Patnaik A., Rosen L.S., Tolaney S.M., et al. Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with metastatic breast cancer. Cancer Res. 2014;74(suppl):abstr CT232.

38. Patnaik A., Rosen L.S., Tolaney S.M., et al. LY2835219, a novel cell cycle inhibitor selective for CDK 4/6, in combination with fulvestrant for patients with hormone receptor positive (HR+) metastatic breast cancer. J. Clin. Oncol. 2014;32(suppl):abstr 534.

39. Dickler M.N., Barry W.T., Cirrincione C.T., et al. Phase III trial evaluating the addition of bevacizumab to letrozole as first-line endocrine therapy for treatment of hormone-receptor positive advanced breast cancer: CALGB 40503 (Alliance). J. Clin. Oncol. 2015;33(suppl):abstr 501.

40. Rugo H.S., Delord J.P., Im S.A., et al. Preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD-L1–positive, estrogen receptor-positive (ER+)/HER2-negative advanced breast cancer enrolled in KEYNOTE-028. Cancer Res. 2016;76(suppl 4):abstr S5–07.

41. Dirix L.Y., Takacs I., Nikolinakos P., et al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase Ib JAVELIN solid tumor trial. Cancer Res. 2016;76(suppl 4):abstr S1–04.

42. Slamon D.J., et al. Ribociclib+fulvestrant in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: Results from MONALEESA-3. Presented at 2018 ASCO Annual meeting. June 1–5, 2018, Chicago, IL. Poster 1000

43. Hortobagyi G.N. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018;29:1541–47.

44. https://www.novartis.com/news/media-releases/novartis-kisqalir-now-first-and-only-cdk46-inhibitor-indicated-us-first-line-therapy-specifically-premenopausal-women-and-initial-therapy-fulvestrant

45. Tripathy D., et al. First-line ribociclib or placebo combined with goserelin and tamoxifen or a non-steroid aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer. Results from randomized Phase III MONALEESA-7 tr. Oral presentation at San Antonio Breast Cancer Symposium – 40th Annual Meeting:2017.


Об авторах / Для корреспонденции


Автор для связи: К.С. Николаев, врач-онколог, науч. сотр. отделения опухолей молочной железы, НИИ онкологии им. Н.Н. Петрова, Санкт-Петербург, Россия; e-mail: kirill.nikolaev87@gmail.com
Адрес: 197758, Россия, Санкт-Петербург, пос. Песочный, ул. Ленинградская, 68


Похожие статьи


Бионика Медиа